Skip to content

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07579845
Enrollment
60
Registered
2026-05-12
Start date
2026-05-05
Completion date
2026-09-01
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biological Aging, Detoxification, Inflammation

Brief summary

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

Interventions

DIETARY_SUPPLEMENTHumic and Fulvic Acid Dietary Supplement

BioToxin Binder (CellCore Biosciences, Palm Beach Gardens, FL) - Humic and Fulvic Acid Dietary Supplement

Sponsors

OvationLab
Lead SponsorNETWORK

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Adult females or males age ≥ 40 years 2. Ability to read and speak English

Exclusion criteria

1. Current use of a dietary supplement containing fulvic or humic acid 2. Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella 3. Known allergies to any ingredients in the product 4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks 5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol 6. Participants unable to provide consent

Design outcomes

Primary

MeasureTime frameDescription
TruDiagnostic - Epigenetic TestingChange in TruAge from baseline to 12 weeksTruAge Test

Countries

United States

Contacts

CONTACTStudy Administrator
info@ovationlab.com(240) 232-2103

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026